Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,207 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low Dose Drug A Clear all

Conditions: Alzheimer Disease, Dementia, Dementia, Vascular, Pain
Interventions: hydrocodone/APAP w placebo PRN, hydrocodone/APAP, placebo with hydrocodone/APAP PRN; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 55 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 3
States / cities: Tuscaloosa, Alabama

Conditions: Metastatic Prostate Cancer
Interventions: Naltrexone; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Malignant Melanoma
Interventions: Interleukin-2, Temozolomide; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Multiple Myeloma
Interventions: Stem cell transplant x 1 or x 2, lenalidomide and dexamethasone; Procedure · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more

Conditions: Dysthymic Disorder, Depressive Disorder NOS
Interventions: Duloxetine (Cymbalta); Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 20 Years to 75 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Partial Onset Seizures
Interventions: Investigational new drug, company code: BGG492, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 10 more

Conditions: Ototoxicity, Drug-Induced
Interventions: ORC-13661, Placebo; Drug
Lead sponsor: Kevin Winthrop; Other
Eligibility: 18 Years to 80 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: San Francisco, California • Denver, Colorado • Baltimore, Maryland + 5 more

Conditions: Beta-Caryophyllene
Interventions: Low Dose Beta-Caryophyllene, Medium Dose Beta-Caryophyllene, High Dose Beta-Caryophyllene, Placebo; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Alcohol Dependence, Depression
Interventions: Mecamylamine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorder, Genetics
Interventions: Sirolimus; Drug
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 3 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV-1-infection, Aging, Premature, Cognitive Impairment, Memory Impairment, HIV-Associated Cognitive Motor Complex
Interventions: Scopolamine Injectable Product, Mecamylamine Pill; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 35 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Sickle Cell Disease
Interventions: Allogeneic Non-Myeloablative Stem Cell Transplantation, Alemtuzumab, Sirolimus; Procedure · Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 16 Years to 60 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pilomyxoid Astrocytoma, Pilocytic Astrocytoma, Glioma, Astrocytic, Optic Nerve Glioma, Pleomorphic Xanthoastrocytoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliosarcoma, Diffuse Intrinsic Pontine Glioma, DIPG, Low-grade Glioma, Brainstem Glioma
Interventions: Mebendazole, Vincristine, Carboplatin, Temozolomide, Bevacizumab, Irinotecan; Drug
Lead sponsor: Julie Krystal; Other
Eligibility: 1 Year to 21 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Hodgkin Lymphoma
Interventions: Nivolumab; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Low-Grade Gliomas, Malignant Neoplasms, Brain, Soft Tissue Neoplasms
Interventions: MEK162; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 1 Year to 18 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more

Conditions: Bronchopulmonary Dysplasia, Respiratory Distress Syndrome, Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Interventions: Minimal mechanical ventilation management, Routine mechanical ventilation management, Dexamethasone, Placebo; Procedure · Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 5 Minutes to 10 Days
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 13
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 10 more

Conditions: Gastro Intestinal Bleeding, Upper Gastrointestinal Bleeding
Interventions: Azithromycin Injection, Metoclopramide Injectable Solution, Sodium chloride 0.9%; Drug
Lead sponsor: Waihong Chung; Other
Eligibility: 18 Years and older
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Glioblastoma Multiforme
Interventions: VBI-1901, Carmustine, Lomustine; Biological · Drug
Lead sponsor: VBI Vaccines Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 12
States / cities: Irvine, California • La Jolla, California • Los Angeles, California + 8 more

Conditions: ANCA-associated Vasculitis
Interventions: CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids, Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 39
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more

Conditions: Healthy Volunteers, Diabetes Mellitus, Type 1
Interventions: 18 F-FP-DTBZ, PET Scanning; Drug · Radiation
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Triglycerides
Interventions: Curcumin (Longvida™), Half Dose Curcumin (Longvida™), Astaxanthin, Placebo Control; Dietary Supplement · Other
Lead sponsor: Medinutra LLC; Other
Eligibility: 21 Years to 59 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Dublin, Ohio

Conditions: Myopia
Interventions: Atropine 0.01% Ophthalmic Solution, Atropine 0.02% Ophthalmic Solution, Atropine 0.05% Ophthalmic Solution; Drug
Lead sponsor: University of California, Berkeley; Other
Eligibility: 18 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Opioid Dependence
Interventions: Buprenorphine; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Tobacco Use Cessation
Interventions: Varenicline, Nicotine Patch, Placebo Patch, Placebo Tablet, Questionnaires, Counseling Sessions, Lab Session, Saliva Test; Drug · Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)

Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Duloxetine for Chronic Depression: a Double-blind Study

Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures

Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

Acute Changes In Thermal Pain Response Following Single Oral Dose of Beta-Cary

Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence

Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation

Mental Ability Challenge Study in Adults With and Without HIV

Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)

A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS

Study of MEK162 for Children With Low-Grade Gliomas

Minimal Breathing Support and Early Steroids to Prevent Chronic Lung Disease in Extremely Premature Infants (SAVE)

Metoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis

Evaluation of 18 F-FP-DTBZ Pancreatic PET Scanning as a Tool to Measure Beta Cell Mass

Curcumin & Astaxanthin for Lowering Triglyceride Readings and Inflammation

An Investigation of Topical Ophthalmic Low-Dose Atropine on Pupil Size and Accommodation

Buprenorphine Treatment for Opioid Dependence

Reward Sensitivity and Pharmacotherapy for Smoking Cessation